Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Cigna plans to remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less-pricey biosimilar versions of ...

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more Zepbound pricing changes may not expand access as much as Lilly has indicated Alex Hogan/STAT ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

In November 2023, the U.S Food and Drug Administration (FDA) approved Zepbound (tirzepatide), an injectable prescription medicine that may help adults with obesity, excess weight (overweight) or ...

The FDA’s website states that Eli Lilly’s popular weight loss drugs Zepbound and Mounjaro have "limited availability" through the end of April.

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...

Zepbound is a weight loss drug that was approved by the Federal Drug Administration on Wednesday. It joins Ozempic and Wegovy as potential tools people seeking to manage their weight can turn to.